Table 3 shows that tamoxifen significantly contributed to the progression of fatty liver [hazard ratio (HR): 1.598, 95% confidence interval (CI): 1.173–2.177, P = 0.003] as compared with other treatments modality after adjusting for BMI, progesterone receptor (PR), and FSH. This effect of tamoxifen on fatty liver was consistently meaningful whether or not fatty liver was present at baseline (S1 Table). This evidence concerns the gene PGR and Hepatic steatosis.